ARCT 2138
Alternative Names: ARCT-2138Latest Information Update: 12 Jan 2024
At a glance
- Originator Arcturus Therapeutics
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Dendritic cell modulators; Protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Influenza virus infections
Most Recent Events
- 22 Jan 2024 Phase-I clinical trials in Influenza virus infections (Prevention) in Australia (IM) , (NCT06125691)
- 17 Nov 2023 Arcturus Therapeutics plans phase I trial in Influenza virus infections in Australia in December 2023 (IM) (NCT06125691)
- 17 Nov 2023 ARCT 2138 is available for licensing as of 17 Nov 2023. https://arcturusrx.com/mrna-medicines-pipeline/